FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Celgene's Trailing 12-Month Free Cash Flow is ARS0.00 Mil, and Market Cap is ARS4,605,377.62 Mil. Therefore, Celgene's FCF Yield % for today is 0.00%.
The historical rank and industry rank for Celgene's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Celgene was 4.64%. The lowest was 2.48%. And the median was 3.09%.
BUE:CELG's FCF Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.67 * Ranked among companies with meaningful FCF Yield % only.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Celgene FCF Yield % Related Terms
Celgene FCF Yield % Historical Data
* Premium members only.
The historical data trend for Celgene's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:CELG vs GILD, BIIB, ACT: FCF Yield % Comparison
For the Drug Manufacturers - General subindustry, Celgene's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Celgene's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celgene (BUE:CELG) has a FCF Yield % of 0.00 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Celgene and its competitors. Over the past decade, Celgene's FCF Yield % has ranged from 2.48 to 4.64.
Is Celgene's FCF Yield % too high?
Celgene's current FCF Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 4.64. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's FCF Yield % compare to GILD and BIIB?
Celgene's FCF Yield % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median FCF Yield % is 0.67. Historically, Celgene's own FCF Yield % has ranged from 2.48 to 4.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current FCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current FCF Yield % of 0.00. The current FCF Yield % is 0.00. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Celgene (BUE:CELG), the current FCF Yield % is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 